Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Fructooligosaccharides (FOS) & Non-Alcoholic Steatohepatitis (NASH / MASH)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

NCT03184376 - Fructooligosaccharides (FOS) & Non-Alcoholic Steatohepatitis (NASH / MASH)

This randomized, placebo-controlled clinical pilot treatment trial revealed that Fructooligosaccharides (FOS), when considered independently of other lifestyle modifications, was found to reduce histologically-confirmed steatosis in patients suffering from NASH. It is suggested that larger follow-up studies should be conducted to further explore these finding (1).

References

(1) Bomhof et al. 2019 Eur J Nutr 58: 1735-1745

…

References (Sources)

Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial
Bomhof et al. 2019 Eur J Nutr 58: 1735-1745

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!